Sugi Predict

Sugi Predict / Targets / UBA1

UBA1

Ubiquitin-like modifier-activating enzyme 1 · P22314 · UBA1 on Sugi Atlas →

1,596 patent compounds predicted against UBA1, 1,275 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL15191832 SCHEMBL15191832 1.00 20/20
SCHEMBL15191950 SCHEMBL15191950 1.00 20/20
SCHEMBL15192024 SCHEMBL15192024 1.00 20/20
SCHEMBL15198144 SCHEMBL15198144 1.00 20/20
SCHEMBL15198146 SCHEMBL15198146 1.00 20/20
SCHEMBL15198148 SCHEMBL15198148 1.00 20/20
SCHEMBL15198150 SCHEMBL15198150 1.00 20/20
SCHEMBL15198154 SCHEMBL15198154 1.00 20/20
SCHEMBL15198156 SCHEMBL15198156 1.00 20/20
SCHEMBL15198158 SCHEMBL15198158 1.00 20/20
SCHEMBL15198159 SCHEMBL15198159 1.00 20/20
SCHEMBL15198165 SCHEMBL15198165 1.00 20/20
SCHEMBL15198171 SCHEMBL15198171 1.00 20/20
SCHEMBL15198173 SCHEMBL15198173 1.00 20/20
SCHEMBL15198202 SCHEMBL15198202 1.00 20/20
SCHEMBL15198210 SCHEMBL15198210 1.00 20/20
SCHEMBL15198211 SCHEMBL15198211 1.00 20/20
SCHEMBL15198216 SCHEMBL15198216 1.00 20/20
SCHEMBL15198218 SCHEMBL15198218 1.00 20/20
SCHEMBL15198219 SCHEMBL15198219 1.00 20/20

Clinical trials — most relevant to UBA1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients PHASE4NOT_YET_RECRUITING
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit PHASE2/PHASE3WITHDRAWN
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma PHASE2SUSPENDED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study PHASE2WITHDRAWN
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
HRQoL and Financial Toxicity in Patients With VEXAS Syndrome nanRECRUITING
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 nanRECRUITING
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome nanRECRUITING
A Natural History Study of Angelman Syndrome nanRECRUITING
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure nanCOMPLETED
Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome nanCOMPLETED
The Significance of Urine UbA52 In the Diagnosis of Diabetic Nephropathy nanCOMPLETED
Evaluation of Biomarker Kinetics After Mild Brain Injury Trauma nanCOMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Safety and Tolerability of a Nutritional Formula Designed to Aid in Maintenance of Muscle During Periods of Caloric Restriction in Adults nanNOT_YET_RECRUITING
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit nanCOMPLETED
A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS nanRECRUITING
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC) nanUNKNOWN
Relationship Between Nutritional State and Respiratory Muscle Weakness in Adult Patients With Bronchietasis nanUNKNOWN
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin nanUNKNOWN
Neuronal and Glial Biomarkers in Stroke nanCOMPLETED
Clinical Study of Muenke Syndrome (FGFR3-Related Craniosynostosis) nanCOMPLETED
NLRP3 Inflammasome and Physical Therapy in ICU-Acquired Weakness nanRECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Genetic Characterization of Parkinson's Disease nanCOMPLETED
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex nanCOMPLETED
Association of Autophagy-related Genes ,LncRNA and SNPs With Colorectal Cancer in Egyptian Population nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a UBA1 binder may also engage these)

ProteinNameSimilarity
A3KMV5 — 1.000 A3KMV5 →
Q29504 — 1.000 Q29504 →
Q5U300 — 1.000 Q5U300 →
Q02053 — 0.998 Q02053 →
P31254 — 0.991 P31254 →
Q7ZY60 — 0.981 Q7ZY60 →
PC Pyruvate carboxylase, mitochondrial 0.981 landscape →
Q9V6U8 — 0.981 Q9V6U8 →
Q642Q1 — 0.980 Q642Q1 →
P52873 — 0.977 P52873 →
Q641Y5 — 0.976 Q641Y5 →
O94609 — 0.975 O94609 →
Q29RK2 — 0.975 Q29RK2 →
O65041 — 0.975 O65041 →
PRMT5 Protein arginine N-methyltransferase 5 0.974 landscape →
P28227 — 0.974 P28227 →
Q9UDR5 — 0.974 Q9UDR5 →
A8E657 — 0.974 A8E657 →
UBA2 SUMO-activating enzyme subunit 2 0.973 landscape →
Q8BMF3 — 0.973 Q8BMF3 →
Q9Z1F9 — 0.973 Q9Z1F9 →
Q6YXZ7 — 0.972 Q6YXZ7 →
P40927 — 0.972 P40927 →
Q8CIG8 — 0.972 Q8CIG8 →
ME1 NADP-dependent malic enzyme 0.972 landscape →
Q05920 — 0.972 Q05920 →
Q9YH58 — 0.972 Q9YH58 →
Q55C16 — 0.972 Q55C16 →
A7YW45 — 0.971 A7YW45 →
Q9D906 — 0.971 Q9D906 →